Some barriers to the implementation of such a prevention trial include a lack of data as to whether COX-2 inhibition safely reduces the pro-tumor attributes of breast involution in women, and a lack of validated risk assessment tools to identify women at high risk of developing PPBC. Here, PTGS2 is linked to neoplasm.